Nilotinib HCL Monohydrate CAS No.923288-90-8 Pharmaceutical Intermediates
Introduction
Nilotinib hydrochloride monohydrate is a highly effective oral drug that belongs to the class of tyrosine kinase inhibitors. It is specifically designed to target the BCR-ABL fusion protein, which is responsible for the proliferation of cancer cells in chronic myeloid leukemia (CML). By inhibiting this protein, nilotinib helps control the growth of cancer cells and improves patient outcomes.
As a manufacturer and trader, we pride ourselves on producing high-quality Nilotinib hydrochloride monohydrate to meet the specific needs of our customers in the pharmaceutical industry.
Physical and Chemical Properties
- Appearance: Grey white to light beige powder, stable under standard storage conditions.
- Melting point: about 150-155°C, indicating good thermal stability.
- Solubility: Highly soluble in water and organic solvents, thereby enhancing its bioavailability and therapeutic effect.
- pH: Slightly acidic, which can be beneficial in some formulations.
These properties not only enhance the reactivity of the compound but also ensure its compatibility with a wide range of other chemicals used in drug formulations.
1. Effective Treatment for CML: Nilotinib hydrochloride monohydrate is specifically indicated for the treatment of chronic myeloid leukemia, providing a targeted treatment for this serious disease.
2. Improved bioavailability: The monohydrate form significantly improves the solubility and absorption rate of nilotinib, thereby achieving more effective dosing and better therapeutic effect.
3. High Purity and Quality: Our stringent quality control process ensures that Nilotinib HCl monohydrate is of high purity, minimizing impurities that may affect the efficacy of the final drug product.
4. Stable and reliable performance: The chemical stability of Nilotinib HCl monohydrate ensures that it maintains its properties over time and provides consistent results in a variety of applications.
5. Regulatory Compliance: Our manufacturing processes comply with Good Manufacturing Practices (GMP) and other international regulations, ensuring our products meet the highest safety and quality standards.
Nilotinib hydrochloride monohydrate is mainly used in the pharmaceutical industry and has a variety of uses:
- Chronic Myeloid Leukemia Treatment: Nilotinib hydrochloride monohydrate is widely used to treat chronic myeloid leukemia, especially in patients who are resistant or intolerant to other therapies. It can effectively reduce the number of cancer cells and improve overall survival.
- Research and Development: Ongoing studies continue to explore the potential of nilotinib hydrochloride monohydrate in new therapeutic areas, underscoring its importance in the pharmaceutical field.
- Combination Therapy: Nilotinib hydrochloride monohydrate can be used in combination with other cancer therapies to enhance the therapeutic effect and improve patient outcomes.
As a leading manufacturer and trader of Nilotinib HCl Monohydrate, we are committed to providing high-quality products that meet the evolving needs of the pharmaceutical industry. Our commitment to excellence, coupled with our integrated approach to production and trading, makes us a trusted partner for pharmaceutical companies around the world. By choosing our Nilotinib HCl Monohydrate, you can ensure that your formulations meet the highest standards of quality and efficacy, ultimately helping to improve patient outcomes.
To learn more about our products and services, please contact us today. We look forward to working with you to advance healthcare solutions.